EP0623346A4 - Inhibiteur de la metastase d'une tumeur maligne. - Google Patents

Inhibiteur de la metastase d'une tumeur maligne.

Info

Publication number
EP0623346A4
EP0623346A4 EP19940913433 EP94913433A EP0623346A4 EP 0623346 A4 EP0623346 A4 EP 0623346A4 EP 19940913433 EP19940913433 EP 19940913433 EP 94913433 A EP94913433 A EP 94913433A EP 0623346 A4 EP0623346 A4 EP 0623346A4
Authority
EP
European Patent Office
Prior art keywords
metastasis
inhibitor
malignant tumor
beraprost
safe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP19940913433
Other languages
German (de)
English (en)
Other versions
EP0623346A1 (fr
EP0623346B1 (fr
Inventor
Masato Mutoh
Masakazu - Chuo Dai- Hattori
Shintaro Nishio
Kiyotaka Ohno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Publication of EP0623346A4 publication Critical patent/EP0623346A4/fr
Publication of EP0623346A1 publication Critical patent/EP0623346A1/fr
Application granted granted Critical
Publication of EP0623346B1 publication Critical patent/EP0623346B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

Un inhibiteur de la métastase de tumeurs malignes, qui est chimiquement stable, peut inhiber, de façon remarquable, la métastase, en toute sécurité. L'inhibiteur présenté contient du béraprost, ou un sel pharmaceutiquement acceptable de celui-ci, comme ingrédient actif.
EP94913433A 1991-04-11 1992-10-09 Inhibiteur de la metastase d'une tumeur maligne Expired - Lifetime EP0623346B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP07881991A JP3230246B2 (ja) 1991-04-11 1991-04-11 悪性腫瘍転移抑制剤
PCT/JP1992/001313 WO1994008584A1 (fr) 1991-04-11 1992-10-09 Inhibiteur de la metastase d'une tumeur maligne
CA002125490A CA2125490C (fr) 1991-04-11 1992-10-09 Agent antimetastatique pour le traitement des tumeurs malignes

Publications (3)

Publication Number Publication Date
EP0623346A4 true EP0623346A4 (fr) 1994-08-29
EP0623346A1 EP0623346A1 (fr) 1994-11-09
EP0623346B1 EP0623346B1 (fr) 2004-05-26

Family

ID=27169790

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94913433A Expired - Lifetime EP0623346B1 (fr) 1991-04-11 1992-10-09 Inhibiteur de la metastase d'une tumeur maligne

Country Status (7)

Country Link
EP (1) EP0623346B1 (fr)
JP (1) JP3230246B2 (fr)
KR (1) KR100268405B1 (fr)
CA (1) CA2125490C (fr)
DE (1) DE69233354T2 (fr)
ES (1) ES2217265T3 (fr)
WO (1) WO1994008584A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3230246B2 (ja) * 1991-04-11 2001-11-19 東レ株式会社 悪性腫瘍転移抑制剤
CN1319011A (zh) * 1999-06-14 2001-10-24 东丽株式会社 药物在肿瘤组织蓄积的增强剂
JP5626755B2 (ja) * 2010-01-12 2014-11-19 国立大学法人群馬大学 走化性運動制御剤
CN103169779B (zh) * 2013-03-12 2016-02-17 北京弘泰安康医药科技有限公司 一种治疗肺癌的药物组合物
CN103720819B (zh) * 2013-12-24 2016-05-04 广州中医药大学 一种治疗稳定期慢性阻塞性肺疾病的中药组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0421562A2 (fr) * 1989-10-05 1991-04-10 Schering Aktiengesellschaft Utilisation d'analogues de la prostacycline contre les métastases
WO1992014438A2 (fr) * 1991-02-12 1992-09-03 Schering Aktiengesellschaft Berlin Und Bergkamen Derives de prostacycline et de carbacycline utiles comme agents therapeutiques de maladies febriles
JPH04312531A (ja) * 1991-04-11 1992-11-04 Toray Ind Inc 悪性腫瘍転移抑制剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57144276A (en) * 1981-03-03 1982-09-06 Toray Ind Inc 5,6,7-trinor-4,8-inter-m-phenylene pgi2 derivative
JPS58124778A (ja) * 1982-01-20 1983-07-25 Toray Ind Inc ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0421562A2 (fr) * 1989-10-05 1991-04-10 Schering Aktiengesellschaft Utilisation d'analogues de la prostacycline contre les métastases
WO1992014438A2 (fr) * 1991-02-12 1992-09-03 Schering Aktiengesellschaft Berlin Und Bergkamen Derives de prostacycline et de carbacycline utiles comme agents therapeutiques de maladies febriles
JPH04312531A (ja) * 1991-04-11 1992-11-04 Toray Ind Inc 悪性腫瘍転移抑制剤

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"accession number 07133831", DIALOG INFORMATION SERVICES, FILE 155: MEDLINE *
CHEMICAL ABSTRACTS, vol. 118, no. 13, 29 March 1993, Columbus, Ohio, US; abstract no. 116744e *
M.R.SCHNEIDER ET AL.: "Antimetastatic prostacyclin analogs", DRUGS FUTURE, vol. 18, no. 1, 1993, pages 29 - 48 *
See also references of WO9408584A1 *
Y.KURATA ET AL., J. TOXICOL. SCI., vol. 14, no. SUP1, August 1989 (1989-08-01), pages 1 - 39 *

Also Published As

Publication number Publication date
DE69233354D1 (de) 2004-07-01
DE69233354T2 (de) 2005-06-02
EP0623346A1 (fr) 1994-11-09
EP0623346B1 (fr) 2004-05-26
JP3230246B2 (ja) 2001-11-19
JPH04312531A (ja) 1992-11-04
ES2217265T3 (es) 2004-11-01
KR100268405B1 (ko) 2000-10-16
CA2125490A1 (fr) 1994-04-28
WO1994008584A1 (fr) 1994-04-28
CA2125490C (fr) 2003-08-05

Similar Documents

Publication Publication Date Title
AU3074289A (en) 2,2'-iminobisethanol derivatives as potentiators of the effects of blood pressure reducing agents
AU6613896A (en) Chemical compounds
GR3032929T3 (en) Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor compound.
MY104926A (en) Quinoline, quinazoline and cinnoline derivatives
CA2112014A1 (fr) Composition antiallergique pour usage ophtalmique ou nasal
CA2064634A1 (fr) Derives de 9-desoxo-8a-aza-8a-homoerythromycine a modifies en positions 4"- et 8a
ITBO930097A1 (it) Apparecchio per l'equilibratura dinamica di un corpo rotante.
PL309282A1 (en) Application of 2-amino-6-n-propyl-amino- 4,5,6,7-tetrahydrobenzothiasole (pramipexol) as an antidepressant
AU2521597A (en) Piperidinylpyramidine derivatives
AU6165894A (en) Use of creatine or analogs for the manufacture of a medicament for inhibiting tumor growth
HUP0002239A3 (en) The use of thienopyrimidine derivatives for combating fungi
JO1704B1 (en) New potent compounds
AU1417092A (en) 1-imidazolgemethyl benzofuran derivatives as inhibitors of angiotensin ii activity
AU3808289A (en) Pharmaceutical compositions for the inhibition of tumor metastasis
WO2000005214A3 (fr) Isoquinoleines utilisees en tant qu'inhibiteurs de l'urokinase
EP0610519A4 (en) Anti-hiv drug.
MD502G2 (ro) Derivaţi noi ai adenozinei, procedee de preparare a lor, compoziţii farmaceutice ce le conţin
EP0171477A3 (fr) Composés therapéutiques contenant des acides aminés
AU7728691A (en) Use of substituted beta-hydroxyethylamines as potent inhibitors of the exoenzymes of fungi
EP0623346A4 (fr) Inhibiteur de la metastase d'une tumeur maligne.
MY104162A (en) A hydrazone compound and production therefor, and an insecticidal composition containing the same.
EP1026162A4 (fr) Agent anti-rhumatismal
DE69006931D1 (de) Ghilanten: antimetastatischer Wirkstoff aus dem südamerikanischen Blutegel Haementeria Ghilianii.
TW325472B (en) A pharmaceutical composition for preventing cancer comprising 2-(1-hydroxyethyl)-5-hydroxynaphto[2,3-b]furan-4,9-dione
AU642772B2 (en) Inhibitors for the formation of tumor necrosis factor, processes for the preparation thereof and the use thereof

Legal Events

Date Code Title Description
A4 Supplementary search report drawn up and despatched
AK Designated contracting states

Kind code of ref document: A4

Designated state(s): BE CH DE ES FR GB IT LI NL SE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940610

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE ES FR GB IT LI NL SE

17Q First examination report despatched

Effective date: 20011109

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): BE CH DE ES FR GB IT LI NL SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040526

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040526

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040526

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040526

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 69233354

Country of ref document: DE

Date of ref document: 20040701

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040826

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2217265

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20050301

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20081014

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20081030

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20081028

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20081014

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20081008

Year of fee payment: 17

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20100630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091102

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100501

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091009

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20110324

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091009

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110310

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091010